Olema Oncology
Ms. Butitta has served as a member of the Board of Directors since August 2020. She most recently served as Chief Operating Officer of Kite Pharma Inc. Before Kite, she was Senior Vice President and Chief Financial Officer at NextWave Pharmaceuticals, Inc. Earlier in her career, she held roles of increasing leadership at Telik, Inc., including Chief Operating Officer, Chief Financial Officer, and Principal Accounting Officer. She is a member of the Boards of Directors of Autolus Therapeutics plc and UroGen Pharma Ltd. Ms. Butitta received a B.S. with honors in business and accounting from Edgewood College in Madison, Wisconsin, and an M.B.A. in finance from the University of Wisconsin, Madison.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.